Has Andrew Sumner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $838 in general payments to Andrew Sumner, MD across 12 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Sumner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Sumner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Sumner, MD

Cardiovascular Disease · Allentown, PANPI 1114975737

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Medtronic at 31.3% of the total. Reporting peaked in 2019 at $372 and has fallen 64.2% since, to $133 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in PA, where the typical reported total is $1,447.

$838in general payments, 2019–2025

Across 12 payments — averaging $69.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$262
Abbott$253
Boston Scientific$142
GE HealthCare$114
Abiomed$45
AstraZeneca$21

$196,213in research payments, 2019–2025

Across 31 payments — averaging $6329.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$156K
CSL Behring$22K
AstraZeneca$10K
Astrazeneca UK Limited$8K

What the payments were for

Food & beverage$838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	3	$262
Abbott	2	$253
Boston Scientific	3	$142
GE HealthCare	2	$114
Abiomed	1	$45
AstraZeneca	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$838 in reported general payments places this provider in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$71,844

Medicare patients

566

Services billed

1,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	278	$331,715
Repatha SureclickEvolocumab	295	$241,644
Praluent PenAlirocumab	121	$88,910
XareltoRivaroxaban	39	$56,520
EntrestoSacubitril/Valsartan	32	$52,338
VascepaIcosapent Ethyl	62	$47,176
JardianceEmpagliflozin	23	$36,103
Icosapent Ethyl	78	$20,141
Repatha SyringeEvolocumab	11	$14,558
Ezetimibe	414	$11,284
NexletolBempedoic Acid	16	$10,909
Metoprolol Succinate	494	$9,577
Rosuvastatin Calcium	311	$4,278
Dofetilide	11	$4,141
Atorvastatin Calcium	319	$3,845

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Allentown

Sabahat BokhariAllentown$578K
Matthew MartinezAllentown$419K
Steven ZelenkofskeAllentown$103K
Bryan KluckAllentown$60K
Hemal GadaWormleysburg$1.8M
Benjamin KalsmithPgh$1.7M
Peter KoweyWynnewood$1.5M
Paul ForfiaPhiladelphia$1.2M
Quang BuiPhiladelphia$933K
Rhian DaviesYork$853K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →